Biotech RadarJobs updated

COMPANY

Larimar Therapeutics

HQ: Bala Cynwyd, PA source · larimartx.com ↗

Clinical Phase 3

9 open jobs · last seen Oct 23, 2026 · 10 sources

Keywords: rare disease rare diseases Friedreich ataxia Friedreich's Ataxia CTI-1601 Nomlabofusp

Location: Bala Cynwyd, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

9Open jobs$169.0MRaised (2 yrs)8Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Director, Medical AffairsPhiladelphia, PASep 4, 2026Oct 16, 2026
Director, Regulatory Affairs, Ex-USPhiladelphia, PAAug 31, 2026Oct 16, 2026
Senior Director, Safety & PharmacovigilancePhiladelphia, PAAug 25, 2026Oct 16, 2026
Senior Manager, Clinical QualityPhiladelphia, PAAug 25, 2026Oct 16, 2026
Manager, Drug Product ManufacturingPhiladelphia, PAAug 12, 2026Oct 16, 2026

See all 9 jobs

Timeline

  1. Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia source ↗
  2. Raise Follow-on offering: $100M (total, as published), announced Feb 26, 2026. Source: company release on GlobeNewswire. source ↗
  3. Raise Follow-on offering: $69M (total, as published), announced Jul 31, 2025. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 1: A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia source ↗
  5. Trial start Phase 2: An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia source ↗
  6. Trial start Phase 2: A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia source ↗
  7. Trial start —: Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers source ↗
  8. Trial start Phase 1: Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia source ↗
  9. Trial start —: A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia source ↗
  10. Trial start Phase 1: Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $169.0M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT07778836A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaPhase 3RecruitingOct 26, 20262029-07 (estimated)
NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaPhase 2RecruitingJan 25, 20242027-01 (estimated)
NCT06681766A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's AtaxiaPhase 1TerminatedDec 6, 2024Apr 27, 2025 (actual)
NCT05579691A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaPhase 2CompletedSep 21, 2022Dec 4, 2023 (actual)
NCT05028764Determine Range of Tissue Frataxin Concentrations and Other Potential BiomarkersNot listedCompletedAug 4, 2021Feb 4, 2022 (actual)
NCT04519567Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaPhase 1CompletedJul 31, 2020Mar 16, 2021 (actual)
NCT04176991Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaPhase 1CompletedDec 11, 2019Oct 31, 2020 (actual)
NCT04255680A Study to Assess Variation in Potential Biomarkers in Friedreich AtaxiaNot listedCompletedJan 14, 2020Jun 30, 2020 (actual)

Open jobs 9

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Director, Medical AffairsPhiladelphia, PASep 4, 2026Oct 16, 2026Not stated
Director, Regulatory Affairs, Ex-USPhiladelphia, PAAug 31, 2026Oct 16, 2026Senior
Senior Director, Safety & PharmacovigilancePhiladelphia, PAAug 25, 2026Oct 16, 2026Senior
Senior Manager, Clinical QualityPhiladelphia, PAAug 25, 2026Oct 16, 2026Senior
Manager, Drug Product ManufacturingPhiladelphia, PAAug 12, 2026Oct 16, 2026Senior
Medical Science LiaisonField Based, PAAug 4, 2026Oct 16, 2026Not stated
Associate Director, Quality (Validation and Data Integrity)Philadelphia, PAJul 21, 2026Oct 16, 2026Senior
Vice President, MedicalPhiladelphia, PAMay 20, 2026Oct 16, 2026Executive
Director, Business DevelopmentPhiladelphia, PAMar 18, 2026Oct 16, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Feedback